Regenxbio Inc (NAS:RGNX)
$ 7.41 -0.46 (-5.84%) Market Cap: 367.13 Mil Enterprise Value: 218.52 Mil PE Ratio: 0 PB Ratio: 1.22 GF Score: 65/100

Q3 2022 Regenxbio Inc Earnings Call Transcript

Nov 03, 2022 / 12:30PM GMT
Release Date Price: $21.05 (-13.16%)
Operator

Hello, and thank you for standing by. Welcome to the Q3 2022 REGENXBIO Inc. earnings call and update on Altitude. (Operator Instructions). It is now my pleasure to introduce Chief Legal Officer, Patrick Christmas.

Patrick J. Christmas
REGENXBIO Inc. - Executive VP & Chief Legal Officer

Good morning, and thank you for joining us today. Earlier this morning, REGENXBIO released financial and operating results for the third quarter ended September 30, 2022, as well as new data from our Altitude trial. The press releases and data presentation are available on our website at www.regenxbio.com. Today's conference call will include forward-looking statements regarding our financial outlook and our development of RGX-314, in addition to regulatory and product development plans. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted and can be identified by words such as expect, plan, will, may, anticipate, believe, should,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot